Your session is about to expire
← Back to Search
FlowSense Monitoring for Hydrocephalus (RHAEOS Trial)
RHAEOS Trial Summary
This trial tech aims to improve care for those suffering from hydrocephalus, providing a wireless, noninvasive way to monitor CSF flow in shunts and reduce unnecessary imaging, hospital stays & readmissions.
RHAEOS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RHAEOS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Phase B
- Group 2: Phase A:
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this trial still open?
"Data on clinicaltrials.gov shows that this research is actively recruiting subjects. It was first posted on July 11th, 2023 and last updated 14 days later."
Is the age range for this research project inclusive of individuals aged 55 or greater?
"According to the study's entry requirements, only individuals 1 year and older up to 21 years are eligible. Furthermore, there are 5 medical trials catered specifically for minors (below 18) and a total of 18 clinical studies open for seniors over 65."
Is it feasible to enroll in this research trial?
"This experiment is seeking 24 minors between 1 and 21 years old who possess hydrocephalus in addition to an existing external ventricular drain (EVD)."
How many volunteers are taking part in this experiment?
"Affirmative. As indicated by the information on clinicaltrials.gov, this trail is currently enrolling participants since July 11th 2023 and was last updated 14 days later. 24 people are required to take part in the trial at a single site."
Share this study with friends
Copy Link
Messenger